Which is the Preferred Regimen for Non-Severe Clostridioides difficile Infection in Korea, Vancomycin or Metronidazole?

키워드

참고문헌 (44)

1. "Antibiotic resistance threats in the United States, 2019"[URL]
2. Cohen SH, "Clinical practice guidelines for Clostridium difficile infection in adults : 2010 update by the society for healthcare epidemiology of America(SHEA)and the infectious diseases society of America(IDSA)", Infect Control Hosp Epidemiol, 31, pp.431~455 (2010)
3. McDonald LC, "Clinical practice guidelines for Clostridium difficile infection in adults and children : 2017 update by the Infectious Diseases Society of America(IDSA)and Society for Healthcare Epidemiology of America(SHEA)", Clin Infect Dis, 66, pp.e1~48 (2018)
4. Johnson S, "Clinical practice guideline by the Infectious Diseases Society of America(IDSA)and Society for Healthcare Epidemiology of America(SHEA) : 2021 focused update guidelines on management of Clostridioides difficile infection in adults", Clin Infect Dis, 73, pp.e1029~e1044 (2021)
5. Surawicz CM, "Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections", Am J Gastroenterol, 108, pp.478~498 (2013)
6. Kelly CR, "ACG clinical guidelines : Prevention, diagnosis, and treatment of Clostridioides difficile infections", Am J Gastroenterol, 116, pp.1124~1147 (2021)
7. Bauer MP, "European Society of Clinical Microbiology and Infectious Diseases(ESCMID) : treatment guidance document for Clostridium difficile infection(CDI)", Clin Microbiol Infect, 15, pp.1067~1079 (2009)
8. Debast SB, "European Society of Clinical Microbiology and Infectious Diseases : update of the treatment guidance document for Clostridium difficile infection", Clin Microbiol Infect, 20(Suppl 2), pp.1~26 (2014)
9. van Prehn J, "European Society of Clinical Microbiology and Infectious Diseases : 2021update on the treatment guidance document for Clostridioides difficile infection in adults", Clin Microbiol Infect, 27(Suppl 2), pp.S1~S21 (2021)
10. Clancy CJ, "Impact of revised Infectious Diseases Society of America and Society for Healthcare Epidemiology of America Clinical Practice Guidelines on the treatment of Clostridium difficile infections in the United States", Clin Infect Dis, 72, pp.1944~1949 (2021)
11. 김지은, "Epidemiology and Clinical Characteristics of Clostridium difficile Infection in a Korean Tertiary Hospital", Journal of Korean Medical Science, 26(10), pp.1258~1264 (2011), 대한의학회
12. Di X, "A meta-analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity", Braz J Infect Dis, 19, pp.339~349 (2015)
13. Nelson RL, "Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults", Cochrane Database Syst Rev, 3, pp.CD004610~ (2017)
14. Li R, "Efficacy and safety of metronidazole monotherapy versus vancomycin monotherapy or combination therapy in patients with Clostridium difficile infection : A systematic review and meta-analysis", PLoS One, 10, pp.e0137252~ (2015)
15. Igarashi Y, "Oral vancomycin versus metronidazole for the treatment of Clostridioides difficile infection : Meta-analysis of randomized controlled trials", J Infect Chemother, 24, pp.907~914 (2018)
16. Polivkova S, "Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection-An observational cohort study", Int J Infect Dis, 103, pp.226~233 (2021)
17. Wenisch JM, "Prospective observational study comparing three different treatment regimes in patients with Clostridium difficile infection", Antimicrob Agents Chemother, 56, pp.1974~1978 (2012)
18. Le F, "A real-world evaluation of oral vancomycin for severe Clostridium difficile infection : implications for antibiotic stewardship programs", Pharmacotherapy, 32, pp.129~134 (2012)
19. Wenisch C, "Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea", Clin Infect Dis, 22, pp.813~818 (1996)
20. Johnson S, "Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection : results from two multinational, randomized, controlled trials", Clin Infect Dis, 59, pp.345~354 (2014)
21. Zar FA, "A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity", Clin Infect Dis, 45, pp.302~307 (2007)
22. Teasley DG, "Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis", Lancet, 2, pp.1043~1046 (1983)
23. Schalk E, "Clostridium difficile-associated diarrhoea, a frequent complication in patients with acute myeloid leukaemia", Ann Hematol, 89, pp.9~14 (2010)
24. Pépin J, "Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada", Clin Infect Dis, 42, pp.758~764 (2006)
25. Martin JS, "Clostridium difficile infection : epidemiology, diagnosis and understanding transmission", Nat Rev Gastroenterol Hepatol, 13, pp.206~216 (2016)
26. Petrella LA, "Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain", Clin Infect Dis, 55, pp.351~357 (2012)
27. Shin BM, "Multicentre study of the prevalence of toxigenic Clostridium difficile in Korea : results of a retrospective study 2000-2005", J Med Microbiol, 57, pp.697~701 (2008)
28. Banawas SS, "Clostridium difficile Infections : A global overview of drug sensitivity and resistance mechanisms", BioMed Res Int, 2018, pp.8414257~ (2018)
29. Saha S, "Increasing antibiotic resistance in Clostridioides difficile : A systematic review and meta-analysis", Anaerobe, 58, pp.35~46 (2019)
30. 김희정, "Investigation of Toxin Gene Diversity, Molecular Epidemiology, and Antimicrobial Resistance of Clostridium difficile Isolated from 12 Hospitals in South Korea", Annals of Laboratory Medicine, 30(5), pp.491~497 (2010), 대한진단검사의학회
31. Byun JH, "A nationwide study of molecular epidemiology and antimicrobial susceptibility of Clostridioides difficile in South Korea", Anaerobe, 60, pp.102106~ (2019)
32. Kim J, "Association between PCR ribotypes and antimicrobial susceptibility among Clostridium difficile isolates from healthcare-associated infections in South Korea", Int J Antimicrob Agents, 40, pp.24~29 (2012)
33. Nicholas A, "Molecular epidemiology and antimicrobial susceptibility of Clostridium difficile isolates from two Korean hospitals", PLoS One, 12, pp.e0174716~ (2017)
34. Hernández Ceruelos A, "Therapeutic uses of metronidazole and its side effects : an update", Eur Rev Med Pharmacol Sci, 23, pp.397~401 (2019)
35. Goolsby TA, "Clinical relevance of metronidazole and peripheral neuropathy : a systematic review of the literature", Int J Antimicrob Agents, 51, pp.319~325 (2018)
36. Kociolek LK, "Breakthroughs in the treatment and prevention of Clostridium difficile infection", Nat Rev Gastroenterol Hepatol, 13, pp.150~160 (2016)
37. Bolton RP, "Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile", Gut, 27, pp.1169~1172 (1986)
38. Abujamel T, "Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole", PLoS One, 8, pp.e76269~ (2013)
39. Lewis BB, "Loss of microbiota-mediated colonization resistance to Clostridium difficile infection with oral vancomycin compared with metronidazole", J Infect Dis, 212, pp.1656~1665 (2015)
40. Gonzales M, "Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection", BMC Infect Dis, 10, pp.363~ (2010)
41. Fishbein SRS, "Randomized controlled trial of oral vancomycin treatment in Clostridioides difficilecolonized patients", MSphere, 6, pp.e00936~20 (2021)
42. Al-Nassir WN, "Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease", Antimicrob Agents Chemother, 52, pp.2403~2406 (2008)
43. Deshpande A, "Effect of fidaxomicin versus vancomycin on susceptibility to intestinal colonization with vancomycinresistant enterococci and Klebsiella pneumoniae in mice", Antimicrob Agents Chemother, 60, pp.3988~3993 (2016)
44. Stevens VW, "Use of oral vancomycin for Clostridioides difficile infection and the risk of vancomycin-resistant enterococci", Clin Infect Dis, 71, pp.645~651 (2020)

관련 논문AI추천